Skip to main content

Search

Global Public Health

Global Public Health  

Throughout our more than 130-year history, Johnson & Johnson has had a legacy of coming to the aid of local and global communities during times of crisis, from natural disasters to health outbreaks. We believe we have a responsibility to step in and invest in solutions for global public health crises and we are immensely proud to be making such significant contributions.                   

COVID-19 has had an unprecedented impact on the world as we know it. The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to rapid scientific progress toward treatment and prevention measures for this global health crisis.

Beginning in January 2020, Johnson & Johnson has worked directly with Governments and health authorities to help end this fast-moving pandemic.

Beyond COVID-19, as a leader in the field of global health, we remain focused on redefining the treatment paradigm for infectious diseases affecting global communities, most notably including diseases like tuberculosis (TB) and Ebola.

We are also working with the not-for-profit Drugs for Neglected Diseases initiative (DNDi) on the pre-clinical programme for a potential new treatment against parasites that cause elephantiasis and river blindness — two of the most difficult-to-treat neglected tropical diseases (NTDs).

International Health Partners (IHP)- Medicines for those in need

We are proud to partner with International Health Partners (IHP) to donate products to crisis-hit communities and help eradicate suffering caused by poor access to medicine. IHP help vulnerable people by overseeing, co-ordinating and delivering strategic medical product donations to those in desperate need of healthcare around the world.

Explore More

 
 
 
 

Looking After Our Environment

 

 

 
 
 

Our Partnerships

 

 

 
 
 

Our Focus

 

 

CP-322384 | June 2022